EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects

Marcelo Gomes Davanço iD, Thaís Pereira Vespasiano, Jessé Moisan iD, Oscar Gonzalez, Milesa Sarmiento, Mélanie Groleau

Pharmaceuticals · 15.07.2026 · 19 (7) · 1089

DOI: 10.3390/ph19071089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 15.07.2026. Verfasst von Marcelo Gomes Davanço und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratorio LKM Chile SpA (a Knight Therapeutics company)., Laboratorio LKM Chile SpA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple myeloma (MM) is a mature B-cell disorder characterized by the excessive production of monoclonal immunoglobulins. It is the second most common hematological cancer and predominantly affects older adults. In 2022, there were approximately 188,000 MM new cases worldwide. The disease is associated with a relapsing–refractory course. First-line therapies are often insufficient, making additional treatment options necessary. For patients refractory to lenalidomide and proteasome inhibitors (bortezomib and/or carfilzomib), pomalidomide combined with dexamethasone and an additional active agent can be used as a therapeutic strategy.

Objective

This study was conducted to evaluate the bioequivalence and tolerability of two pomalidomide hard capsule formulations to support regulatory approval of a branded generic product in Latin American countries.

Methods

An open-label, randomized, single-dose, two-treatment, two-sequence, two-period crossover study was conducted in healthy male subjects. Participants received a single oral dose of the test product, Xetrane® 4 mg hard capsule (Laboratório LKM S.A., Argentina), and the reference product, Imnovid® 4 mg hard capsule (Celgene International Sàrl), with a 7-day washout period. Blood samples were collected over 48 h post-dose. Plasma pomalidomide concentrations were determined using a validated LC-MS/MS method, and pharmacokinetic parameters were estimated using non-compartmental analysis.

Findings

Thirty-four subjects were enrolled, and 29 completed the study. Geometric mean ratios (90% confidence intervals) for Cmax and AUC0–t were 106.24% (100.77–112.00) and 94.67% (91.61–97.82), respectively. Both formulations were well tolerated. Bioequivalence between Xetrane® and Imnovid® was demonstrated in accordance with regulatory criteria. NCT07694011.

Schlagwörter

Stichwörter der Autor:innen

bioavailabilitybioequivalencegenericsmultiple myelomapharmacokineticspomalidomide

Autor:innen und Institutionen

  • Medical & Clinical Affairs Department, United Medical Ltd. (A Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.
  • Medical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.
  • R&D Department, Laboratorio LKM S.A. (A Knight Therapeutics Company), Buenos Aires C1179, Argentina.

ORCID-Profile: Marcelo Gomes Davanço, Jessé Moisan

Förderung

  • Laboratorio LKM Chile SpA (a Knight Therapeutics company).
  • Laboratorio LKM Chile SpA

Zitieren

APA

Davanço, M. G., Vespasiano, T. P., Moisan, J., Gonzalez, O., Sarmiento, M., & Groleau, M. (2026). A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects. Pharmaceuticals, 19(7), 1089. https://doi.org/10.3390/ph19071089

Vancouver

Davanço MG, Vespasiano TP, Moisan J, Gonzalez O, Sarmiento M, Groleau M. A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects. Pharmaceuticals. 2026;19(7):1089. doi:10.3390/ph19071089

BibTeX
@article{Davano2026,
  author = {Davanço, Marcelo Gomes and Vespasiano, Thaís Pereira and Moisan, Jessé and Gonzalez, Oscar and Sarmiento, Milesa and Groleau, Mélanie},
  title = {A Bioequivalence Study Comparing Two Pomalidomide Hard Capsule Formulations in Healthy Chilean Subjects},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1089},
  doi = {10.3390/ph19071089}
}
Kostenlos starten →